Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RAMP202
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
- NCT04620330 ↗
- Completed
- Verastem, Inc.
- Focused
We haven't built an HCP commentary report on RAMP202 (avutometinib (VS-6766) plus defactinib; avutometinib (VS-6766) in recurrent KRAS-mutant or BRAF-mutant non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAMP202 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non Small Cell Lung Cancer; KRAS Activating Mutation
- Interventions
- avutometinib (VS-6766); avutometinib (VS-6766) and Defactinib
- Arms
- Arm 1: avutometinib (VS-6766) monotherapy · Experimental
- Arm 2: avutometinib (VS-6766) in combination with defactinib · Experimental
- Arm 3: avutometinib (VS-6766) in combination with defactinib · Experimental
- Arm 4: avutometinib (VS-6766) in combination with defactinib · Experimental
- Arm 5:avutometinib (VS-6766) in combination with defactinib · Experimental
- Enrollment
- 90
- Primary outcomes
- To determine the optimal regimen, either avutometinib (VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, in KRAS-G12V NSCLC
- To evaluate the initial efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLC
- To determine efficacy in KRAS-other (non-G12V) NSCLC
- To determine the efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLC
- Sponsor
- Verastem, Inc.
- Start
- Dec 31, 2020
- Primary completion
- Aug 29, 2023
- Results posted
- No
- Registry record
- NCT04620330 · updated Jan 12, 2024
Publications
linked from the registry- Capelletto E, Bironzo P, Denis L, Koustenis A, Bungaro M, Novello S. Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncol. 2022 May;18(16):1907-1915. doi: 10.2217/fon-2021-1582. Epub 2022 Mar 14. PubMed 35285277